- Home
- AIXI vs STRO Comparison
AIXI vs STRO Comparison
Compare AIXI & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIXI
- STRO
- Stock Information
- Founded
- AIXI 2001
- STRO 2003
- Country
- AIXI China
- STRO United States
- Employees
- AIXI N/A
- STRO N/A
- Industry
- AIXI Computer Software: Prepackaged Software
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AIXI Technology
- STRO Health Care
- Exchange
- AIXI Nasdaq
- STRO Nasdaq
- Market Cap
- AIXI 43.9M
- STRO 50.0M
- IPO Year
- AIXI 2023
- STRO 2018
- Fundamental
- Price
- AIXI $3.60
- STRO $0.90
- Analyst Decision
- AIXI
- STRO Buy
- Analyst Count
- AIXI 0
- STRO 7
- Target Price
- AIXI N/A
- STRO $6.83
- AVG Volume (30 Days)
- AIXI 104.7K
- STRO 2.1M
- Earning Date
- AIXI 05-06-2025
- STRO 05-12-2025
- Dividend Yield
- AIXI N/A
- STRO N/A
- EPS Growth
- AIXI N/A
- STRO N/A
- EPS
- AIXI N/A
- STRO N/A
- Revenue
- AIXI $65,643,604.00
- STRO $62,043,000.00
- Revenue This Year
- AIXI $22.85
- STRO N/A
- Revenue Next Year
- AIXI $22.70
- STRO $1.29
- P/E Ratio
- AIXI N/A
- STRO N/A
- Revenue Growth
- AIXI 6.22
- STRO N/A
- 52 Week Low
- AIXI $2.06
- STRO $0.52
- 52 Week High
- AIXI $16.08
- STRO $5.17
- Technical
- Relative Strength Index (RSI)
- AIXI 52.54
- STRO 52.79
- Support Level
- AIXI $2.52
- STRO $0.52
- Resistance Level
- AIXI $3.06
- STRO $1.31
- Average True Range (ATR)
- AIXI 0.45
- STRO 0.16
- MACD
- AIXI 0.13
- STRO 0.08
- Stochastic Oscillator
- AIXI 85.62
- STRO 48.43
About AIXI XIAO-I Corporation
XIAO-I Corp is an AI industrialization company focusing on the AI Cognitive Intelligence platform. The platform combines six core technologies including Natural Language Processing, Speech Processing, Computer Vision, Machine Learning, Affective Computing, Data Intelligence, and Hyper- automation. Based on the platform, The company developed products and solutions in the fields of Al+ Contact Center, Al+ Finance, Al+ City Public Service, Al+ Architecture, Al+ Metaverse, Al+ Manufacturing, and Al+ Healthcare. It generates revenue from the sale of software products and services, M&S services, and the sale of cloud platform products.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.